A pharmacology research team is investigating 'Compound Y' as a potential therapeutic agen… — USMLE Step 3

A pharmacology research team is investigating 'Compound Y' as a potential therapeutic agent for chronic heart failure. They perform a series of *in vitro* experiments using isolated cardiac myocytes that express wild-type $\beta_1$ -adrenergic receptors. The team measures intracellular cyclic AMP (cAMP) production as the downstream pharmacodynamic response.

In the first experiment, they plot a dose-response curve for dobutamine, a full $\beta_1$ agonist. They then add a fixed, moderate concentration of Compound Y and repeat the dobutamine dose-response curve. The new curve demonstrates an unchanged maximum cAMP production ( $E_{max}$ ) but a significantly increased $EC_{50}$ for dobutamine.

In the second experiment, the myocytes are exposed to increasing concentrations of Compound Y alone. The researchers observe a dose-dependent increase in cAMP production, but the maximal response plateaus at exactly $40\%$ of the $E_{max}$ achieved by dobutamine.

In the third experiment, a maximal, saturating concentration of dobutamine is applied, producing a $100\%$ cAMP response. Increasing concentrations of Compound Y are then progressively added to this preparation.

Based on the receptor binding properties demonstrated in these experiments, what is the most likely outcome observed in the third experiment?

A
The intracellular cAMP production will remain at $100\%$ because Compound Y cannot displace an agonist with higher intrinsic activity.
The intracellular cAMP production will gradually decrease and plateau at $40\%$ of the maximal dobutamine response.Answer
C
The intracellular cAMP production will decrease to $0\%$ because Compound Y competitively antagonizes the $\beta_1$ -adrenergic receptors.
D
The intracellular cAMP production will decrease and plateau at $60\%$ due to noncompetitive allosteric inhibition by Compound Y.
E
The intracellular cAMP production will increase to $140\%$ because the intrinsic efficacies of both receptor agonists are additive.

Answer

The intracellular cAMP production will gradually decrease and plateau at

40\%

of the maximal dobutamine response.

The correct answer correctly identifies Compound Y as a partial agonist. Experiment 1 (rightward shift of the full agonist curve with unchanged

E_{max}

) demonstrates that Compound Y binds competitively to the same orthosteric site as dobutamine. Experiment 2 establishes that Compound Y possesses an intrinsic activity of

40\%

compared to a full agonist. When a partial agonist is added to a system fully saturated by a full agonist (Experiment 3), it competes for receptor binding sites. As its concentration increases, it will eventually occupy all available receptors, displacing the full agonist. Because it possesses

40\%

intrinsic activity, the receptor response will not drop to zero but will plateau at the partial agonist's maximum efficacy (

40\%

). In this setting, the partial agonist acts as a competitive antagonist, reducing the maximal response.

Step-by-Step Solution

Analyze the results of the first experiment to determine the type of receptor binding.

The unchanged

E_{max}

and increased

EC_{50}

indicate that Compound Y is a competitive ligand binding to the same orthosteric site as the full agonist.

Competitive ligands can be overcome by increasing the concentration of the full agonist, thereby preserving the maximal response while requiring a higher dose to achieve it.

Analyze the results of the second experiment to determine the intrinsic activity (efficacy) of Compound Y.

Compound Y independently produces a response that plateaus at

40\%

of the maximum possible response.

This demonstrates that Compound Y is a partial agonist possessing an intrinsic efficacy of

40\%

Predict the outcome of the third experiment where a partial agonist is added to a system saturated by a full agonist.

As the concentration of the partial agonist increases, it competitively displaces the full agonist from the receptors. The overall response drops from

100\%

and plateaus at

40\%

At saturating concentrations, the partial agonist will occupy all available receptors. Therefore, the response will equal the maximal intrinsic activity of the partial agonist (

40\%

), effectively acting as a functional antagonist.

Key Concept

Pharmacodynamics of Partial Agonists

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic